Piper Jaffray has resumed coverage of NxStage Medical (NASDAQ:NXTM) with an “overweight” rating and $18.50 price target, down from $23 previously. The stock closed at $14.96 on Wednesday. “We have known the story since...
Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to revolutionize the...
In a speech today, President Obama announced that the Department of Health and Human Services (HHS) has issued a new proposed rule to increase the current patient limit for qualified physicians who prescribe...
Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033...
TransEnterix (NYSE MKT:TRXC) has received an update from the FDA on the status of the 510(k) submission for its robotics SurgiBot system to improve minimally invasive surgery. The FDA advised the company that it has not...
Avivagen (TSX-V:VIV) has reported positive results of a trial of OxC-beta Livestock as a feed additive for swine run by COFCO Nutrition and Health Research Institute (COFCO NHRI) of Beijing. The trial evaluated OxC...
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted to the European Medicines Agency (EMA) a protocol design for a Phase 3 trial and registration plan for its lead compound, CF101, in the treatment of rheumatoid...
Venaxis (NASDAQ:APPY), closely-held Strand Life Sciences of India and its U.S. subsidiary, Strand Genomics, have terminated a series of transactions between the companies. The termination affects an asset purchase...
Fourth quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) was $6.8-million, up 28% from $5.3-million a year ago. For all of 2015, revenue rose 28% to $25.2-million from $19.7-million for 2014. A net total of 258 TearLab...
The FDA has provided written feedback to Titan Pharmaceuticals (NASDAQ:TTNP) on the initial development plan for its proprietary ropinirole hydrochloride implant for Parkinson’s disease. Based on the FDA’s feedback on...